on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its ownership in Avadel Pharmaceuticals plc, under Rule 8.3 of the Irish Takeover Panel Act. The disclosure was made on January 28, 2026. The Vanguard Group holds 6.02% interest, equating to 5,867,122 ordinary shares, in Avadel with no short positions reported.
Transactions involving US$0.01 ordinary shares included a recent purchase of 1,944 shares at 21.56 USD per share. This purchase increased Vanguard's position in Avadel, though no new stock-settled derivative agreements were disclosed.
No indemnity or dealing arrangements, such as options or derivatives commitments, were entered into. This filing ensures transparency under the Irish Takeover Regulations for stakeholders in Avadel Pharmaceuticals.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news